Analysts Cite Low Growth in Pediatrix Medical Group Stock
StockStory analysts advise against purchasing Pediatrix Medical Group shares, citing tepid revenue growth and limited upside potential despite recent outperformance. The firm's report, titled "3 Reasons MD is Risky and 1 Stock to Buy Instead," details why the stock does not meet their investment standards. Pediatrix Medical Group shares have risen 17.7% to $26.61 over the past six months, beating the S&P 500 by 5.6%. This recent rally was partly driven by solid quarterly results. However, the analysts argue that long-term sales performance is a better indicator of overall quality than short-term success. They note that Pediatrix Medical Group's annualized revenue growth over the last five years was only 1.7%, which they describe as below their standards. The report highlights that Pediatrix Medical Group generated $1.95 billion in revenue over the past 12 months, classifying it as a small company in an industry where scale matters. In healthcare, a heavily regulated and resource-intensive sector, larger companies benefit from economies of scale that reduce costs per unit and increase bargaining power. Pediatrix Medical Group's smaller size makes it difficult to build trust with customers compared to larger competitors. Looking forward, sell-side analysts expect Pediatrix Medical Group's revenue to rise by 1.5% over the next 12 months. While this projection suggests newer products and services will fuel top-line performance, it remains below the sector average. The stock currently trades at a forward P/E of 11.4, which the analysts consider a reasonable valuation. Nevertheless, they do not see a significant opportunity at the current price of $26.61 per share. The report suggests that investors may find more exciting stocks to buy at the moment, recommending they look at digital advertising picks instead. The analysts emphasize that while Pediatrix Medical Group is not a terrible business, it is not one of their recommended picks due to the lack of compelling growth prospects relative to other opportunities in the market.
StockStory analysts advise against purchasing Pediatrix Medical Group shares, citing tepid revenue growth and limited upside potential despite recent outperformance. The firm's report, titled "3 Reasons MD is Risky and 1 Stock to Buy Instead," details why the stock does not meet their investment standards. Pediatrix Medical Group shares have risen 17.7% to $26.61 over the past six months, beating the S&P 500 by 5.6%. This recent rally was partly driven by solid quarterly results. However, the analysts argue that long-term sales performance is a better indicator of overall quality than short-term success. They note that Pediatrix Medical Group's annualized revenue growth over the last five years was only 1.7%, which they describe as below their standards. The report highlights that Pediatrix Medical Group generated $1.95 billion in revenue over the past 12 months, classifying it as a small company in an industry where scale matters. In healthcare, a heavily regulated and resource-intensive sector, larger companies benefit from economies of scale that reduce costs per unit and increase bargaining power. Pediatrix Medical Group's smaller size makes it difficult to build trust with customers compared to larger competitors. Looking forward, sell-side analysts expect Pediatrix Medical Group's revenue to rise by 1.5% over the next 12 months. While this projection suggests newer products and services will fuel top-line performance, it remains below the sector average. The stock currently trades at a forward P/E of 11.4, which the analysts consider a reasonable valuation. Nevertheless, they do not see a significant opportunity at the current price of $26.61 per share. The report suggests that investors may find more exciting stocks to buy at the moment, recommending they look at digital advertising picks instead. The analysts emphasize that while Pediatrix Medical Group is not a terrible business, it is not one of their recommended picks due to the lack of compelling growth prospects relative to other opportunities in the market.